Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban

Concomitant use of rivaroxaban with non-dihydropyridine calcium channel blockers (non-DHPs) might lead to an increase of systemic rivaroxaban exposure and anticoagulant effects in relation to the inhibition of metabolic enzymes and/or transporters by non-DHPs. This study was designed to evaluate the...

Full description

Bibliographic Details
Main Authors:	Minsoo Kim, Heebin Son, Keumhan Noh, Eunyoung Kim, Beom Soo Shin, Wonku Kang
Format:	Article
Language:	English
Published:	MDPI AG 2019-03-01
Series:	Pharmaceutics
Subjects:	drug–drug interaction PK/PD modeling prothrombin time rivaroxaban verapamil
Online Access:	http://www.mdpi.com/1999-4923/11/3/133

Similar Items

Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita
by: S. N. Bel'diev
Published: (2016-03-01)

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation
by: Huamin Ding, et al.
Published: (2024-07-01)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Lien Thi Ngo, et al.
Published: (2020-10-01)

A methodological review on the pharmacokinetic/pharmacodynamic integration of antibacterial drugs
by: Hongjuan WANG, et al.
Published: (2022-02-01)

Pharmacokinetics and Pharmacodynamics Evaluation of Amoxicillin Against <i>Staphylococcus pseudintermedius</i> in Dogs
by: Ji-Soo Jeong, et al.
Published: (2024-12-01)

Nomogram for predicting bleeding events in nonvalvular atrial fibrillation patients receiving rivaroxaban: A retrospective study
by: Chang Cao, et al.
Published: (2024-01-01)

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects
by: Robert Hoerr, et al.
Published: (2022-04-01)

Verapamil
by: Domingo Arriagada M.
Published: (2017-05-01)

Comparison of the Effect of Verapamil, Nifedipine and Diltiazem on Pentylenetetrazole-Induced Clonic Seizure Threshold in Mice
Published: (2007-09-01)

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
by: Markus Zeitlinger, et al.
Published: (2023-02-01)

Pharmacokinetic Interaction between Metformin and Verapamil in Rats: Inhibition of the OCT2-Mediated Renal Excretion of Metformin by Verapamil
by: Seung Yon Han, et al.
Published: (2020-05-01)

Pharmacodynamics of Rivaroxaban and Dabigatran in Adults with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
by: Teerachat Punnachet, et al.
Published: (2024-10-01)

In vivo pharmacokinetic and pharmacodynamic study and cutoff of florfenicol against Riemerella anatipestifer in ducks
by: Hui-Lin Zhang, et al.
Published: (2025-01-01)

A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation
by: Nan Zhao, et al.
Published: (2022-03-01)

Implementation of Pharmacokinetic and Pharmacodynamic Strategies in Early Research Phases of Drug Discovery and Development at Novartis Institute of Biomedical Research
by: Tove eTuntland, et al.
Published: (2014-07-01)

Comparison of Anticonvulsant Effects of Combined Regimens of Gabapentin and Verapamil with their Individual Effects
by: Itefaq Hussain Qureshi, et al.
Published: (2016-06-01)

Features of drug-drug interactions rivaroxaban and calcium channel blockers depending on the ABCB1 genotype (rs1045642 and rs4148738) in patients 80 years of age and older with non-valvular atrial fibrillation
by: D. A. Sychev, et al.
Published: (2024-01-01)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
by: Xia Xiao, et al.
Published: (2021-01-01)

Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis
by: Xin-Yi Wei, et al.
Published: (2024-04-01)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
by: Zhi Wang, et al.
Published: (2023-10-01)

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
by: Noël Zahr, et al.
Published: (2022-12-01)

Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model
by: Qiaoyi Zhou, et al.
Published: (2017-06-01)

IDENTIFICATION AND QUANTIFICATION OF VERAPAMIL IN BLOOD AND URINE
by: Georgi Bonchev, et al.
Published: (2020-10-01)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
by: Dagmar eKubitza, et al.
Published: (2013-11-01)

Assessing drug-drug interactions of Tacrolimus with Fluconazole and/or Verapamil and developing the predictive model for Tacrolimus concentrations in kidney transplant recipients
by: Mingkwan Na Takuathung, et al.
Published: (2025-06-01)

Pharmacokinetic/pharmacodynamic parameters of vancomycin for predicting clinical outcome of enterococcal bacteremia
by: Eliel Nham, et al.
Published: (2022-08-01)

Pharmacokinetic/pharmacodynamic profiles of baicalin against Mycoplasma gallisepticum in an in vivo infection model
by: Jiaxin Bao, et al.
Published: (2021-11-01)

In- Vivo Comparison of Anticonvulsant Effects of Gabapentin and Verapamil alone and in Combination with Diazepam on Acute Seizure Model
by: Itefaq Hussain Qureshi, et al.
Published: (2017-06-01)

Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug–Drug Interaction between Rivaroxaban and Carbamazepine in Humans
by: Lien Thi Ngo, et al.
Published: (2023-05-01)

Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application
by: Jean Claude Alvarez, et al.
Published: (2022-02-01)

Pharmacokinetic–Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
by: Carmen Flores-Pérez, et al.
Published: (2023-11-01)

Pharmacokinetic/Pharmacodynamic Modeling and Application in Antibacterial and Antifungal Pharmacotherapy: A Narrative Review
by: Laiz Campos Pereira, et al.
Published: (2022-07-01)

Neutropenic Rat Thigh Infection Model for Evaluation of the Pharmacokinetics/Pharmacodynamics of Anti-Infectives
by: Randhir Yedle, et al.
Published: (2023-08-01)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
by: Longfei Zhang, et al.
Published: (2022-03-01)

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban
by: Xiao-Qin Liu, et al.
Published: (2023-02-01)

Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges
by: Huixi Zou, et al.
Published: (2020-07-01)

Suppression of Gelatinase Activity in Human Peripheral Blood Mononuclear Cells by Verapamil
by: Fatemeh Hajighasemi, et al.
Published: (2014-03-01)

Successful Management of Severe Verapamil Overdose with VAECMO
by: Vildan Özer, et al.
Published: (2022-12-01)

Synergistic effect of fosfomycin and colistin against KPC-producing Klebsiella pneumoniae: pharmacokinetics-pharmacodynamics combined with transcriptomic approach
by: Jiajie Zhang, et al.
Published: (2024-10-01)

Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing
by: Hui-Yin Yow, et al.
Published: (2022-06-01)